



Article scientifique

Article

2023

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

Moderating effects of uric acid and sex on cognition and psychiatric symptoms in asymmetric Parkinson's disease

Constantin, Medeleine-Ioana; Voruz, Philippe; Peron, Julie Anne

How to cite

CONSTANTIN, Medeleine-Ioana, VORUZ, Philippe, PERON, Julie Anne. Moderating effects of uric acid and sex on cognition and psychiatric symptoms in asymmetric Parkinson's disease. In: Biology of sex differences, 2023, vol. 14, n° 1, p. 26. doi: 10.1186/s13293-023-00510-1

This publication URL: <https://archive-ouverte.unige.ch/unige:169864>

Publication DOI: [10.1186/s13293-023-00510-1](https://doi.org/10.1186/s13293-023-00510-1)

RESEARCH

Open Access



Moderating effects of uric acid and sex on cognition and psychiatric symptoms in asymmetric Parkinson's disease

Ioana Medeleine Constantin¹, Philippe Voruz^{1,2} and Julie Anne Péron^{1,2*} 

Abstract

Background Non-motor symptoms are an important early feature of Parkinson's disease (PD), encompassing a variety of cognitive and psychiatric symptoms that seem to manifest differently depending on motor symptom asymmetry. Different factors, such as uric acid (UA) and sex, seem to influence cognitive and psychiatric expression in PD, however their interplay remains to be better understood.

Methods Participants taking part in the Parkinson's Progression Marker Initiative were studied based on the side of motor symptom asymmetry and sex. Three-way interaction modeling was used to examine the moderating effects of sex and UA on cognitive functions and psychiatric symptoms.

Results Significant three-way interactions were highlighted at 1-year follow-up between motor symptom asymmetry, UA and sex for immediate and long-term memory in female patients exhibiting predominantly left-sided motor symptoms, and for processing speed and sleepiness in female patients exhibiting predominantly right-sided motor symptoms. No significant interactions were observed for male patients. Moreover, female patients exhibiting predominantly right-sided motor symptoms demonstrated lower serum UA concentrations and had overall better outcomes, while male patients with predominantly right-sided motor symptoms demonstrated particularly poor outcomes.

Conclusions These findings suggest that in the earliest stages of the disease, UA and sex moderate cognitive functions and psychiatric symptoms differently depending on motor asymmetry, holding important clinical implications for symptom management in patients.

Highlights

- Significant three-way interactions were highlighted at 1-year follow-up between motor symptom asymmetry, cognitive–psychiatric symptoms and serum uric acid in female, but not male patients
- Moderation occurred for immediate memory, long-term memory, processing speed and sleepiness
- Uric acid and sex differentially moderated cognitive and psychiatric symptoms depending on the side of motor symptom asymmetry
- Female patients with right-sided symptoms demonstrated the most favorable clinical outcomes and displayed lower levels of serum uric acid

*Correspondence:

Julie Anne Péron

julie.peron@unige.ch

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

- Male patients with right-sided symptoms demonstrated the least favorable neuropsychological outcomes and presented with higher levels of serum uric acid

Keywords Parkinson's disease, Motor symptom asymmetry, Cognition, Psychiatric symptoms, Uric acid, Three-way interaction models

Plain Language Summary

Parkinson's disease is characterized by motor symptoms that usually manifest in an asymmetrical fashion. Given this motor symptom asymmetry, it is possible to distinguish patients that exhibit predominantly right-sided motor symptoms from those that exhibit predominantly left-sided motor symptoms. Patients also often develop non-motor symptoms, such as cognitive and psychiatric complaints. Recent studies have found that non-motor symptoms can manifest differently depending on motor symptom asymmetry. Furthermore, different factors, such as uric acid, a natural antioxidant in the human body, and the patient's sex seem to influence cognitive and psychiatric manifestations, however their interplay remains to be better understood. The present study aimed to examine the interactions between motor symptom asymmetry, serum uric acid and patient's sex on the manifestation of cognitive and psychiatric symptoms. Using regression models, it was found that at 1 year from diagnosis, uric acid and sex moderated cognitive and psychiatric symptoms differently according to motor symptom asymmetry. Indeed, female patients with predominantly left-sided motor symptoms had better memory performances with lower concentrations of serum uric acid, whereas female patients with predominantly right-sided symptoms presented better psychomotor speed and less sleepiness with higher concentrations of uric acid. Moreover, female patients with predominantly right-sided motor symptoms had overall better outcomes, while male patients with predominantly right-sided motor symptoms demonstrated particularly poor clinical outcomes. These findings suggest that in the earliest stages of the disease, uric acid and sex moderate cognitive and psychiatric symptoms differently depending on motor asymmetry, holding important clinical implications for symptom management in patients.

Introduction

Motor symptoms in Parkinson's disease (PD) manifest predominantly in an asymmetrical fashion at the onset of the disease [1], with most de novo PD patients experiencing unilateral motor signs that reflect a contralateral hemispheric loss of dopamine in the substantia nigra [2]. We can thus distinguish patients that exhibit predominantly right-sided motor symptoms (RPD; left hemispheric loss of dopamine) from those that show predominantly left-sided motor symptoms (LPD; right hemispheric loss of dopamine). The clinical picture of PD patients extends however well beyond their motor deficits, encompassing a wide range of non-motor symptoms (NMS) that can manifest years before the onset of motor symptoms, becoming more predominant as the disease progresses [3].

NMS in PD encompass a variety of features, of which cognitive and psychiatric impairments [4], some of which seem to differ based on motor symptom asymmetry [5]. Indeed, from a neuropsychological standpoint, RPD patients seem to show greater cognitive impairment, notably in terms of verbal memory [6, 7], language [8], attention [9] and executive functions [10, 11]. However, LPD patients seem to be more impaired in the visuospatial domain in comparison to

their RPD counterparts [12, 13]. That said, not all cognitive functions appear to be differentially impaired as a function of motor symptom asymmetry, such as inhibitory control [14]. Recent studies that have compared PD patients in early and moderate stages of the disorder have found no differences between LPD and RPD patients [15, 16]. These results were also confirmed in advanced patients in pre- and post-deep brain stimulation of the subthalamic nucleus, where only the bilateral operation restored reactive and proactive inhibitory control [17–19]. Concerning psychiatric symptomatology, different studies have highlighted higher depressive symptoms [20], anxiety [21] and emotion recognition deficits [10] in LPD patients as compared to RPD patients. Moreover, RPD patients seem to present less motor deficits than LPD patients [22]. Such differences in symptoms might be explained in terms of hemispheric vulnerability, with studies highlighting a greater vulnerability of the left hemisphere for cognitive decline in neurodegenerative diseases [23], and a functional insufficiency of the right hemisphere in psychiatric conditions, such as depression [24]. Thus, different patterns of cognitive deficits and psychiatric symptoms seem to emerge on the side of the largest hemispheric damage due to dopaminergic pathway

depletion in PD. Nevertheless, discrepancies persist in the scientific literature concerning motor symptom asymmetry, cognition and psychiatric symptoms, with several studies finding reversed patterns of impairment, and others failing to report any significant differences [4, 25]. Such heterogeneity could reflect a differential effect of various underlying biological factors that interact with symptom expression in the disease.

Recent studies have linked uric acid (UA), a naturally occurring antioxidant in the human body, with a potential neuroprotective role in PD [26]. Serum UA levels seem to be significantly lower in PD, with concentrations further decreasing as the disease progresses [27]. Thus, it has been proposed that higher UA levels in PD patients are associated with a decreased risk of dementia and preserved cognitive function [26, 28]. Indeed, it has been found that baseline serum UA can be a useful marker of cognitive deficits and psychiatric symptom progression in newly diagnosed PD, with higher values corresponding to preserved attention and memory performances [28], as well as diminished symptoms of depression, anxiety [29] and fatigue [30, 31]. Interestingly, UA also seems to be associated to different aspects of motor symptoms in PD, such as motor fluctuations and motor subtypes [31–33]. Notwithstanding, results remain inconclusive, as other studies suggest an opposite effect of high serum UA on cognitive functions [34–36]. The effect of UA on disease symptoms and progression seems to be moderated by participants' sex, possibly explaining the heterogeneous findings of previous studies that didn't consider differences between men and women [37]. Men tend to have greater serum UA concentrations than women, with higher levels of UA being associated to a lowered risk of cognitive impairment, motor fluctuations and disease progression [38]. However, no such association was effectively found in women with PD [26, 32, 39]. Rather, it has been suggested that women may be particularly more vulnerable to the vascular effects of elevated UA [37]. Other than moderating the effects of UA on cognitive outcomes and disease progression, sex-related differences also seem to be at play in the relationship between motor symptom asymmetry, cognition and psychiatric symptoms in PD. While data are scarce concerning the simultaneous effects of asymmetry and sex on cognition, Davidsdottir et al. [40] found that male RPD patients exhibited higher visuospatial impairment compared to female RPD patients, with no differences noted between male and female LPD patients. Also, Bentivoglio et al. [41] highlighted better performances in language tasks for female PD patients, independently of the onset side of motor symptoms.

In summary, different clinical factors, such as motor symptom asymmetry, UA and sex, seem to influence

cognitive and psychiatric manifestations in PD; however, no study has yet examined the interactive effects of these factors. Hence, the present study aims to better understand the interactions between the effects of UA, sex and motor symptom asymmetry on cognition and psychiatric symptoms in early-stage PD. The following predictions were formulated based on the current state of the literature. Using three-way interaction (moderated moderation) models [42], we expected sex and UA to significantly moderate the relationship between motor symptom asymmetry and cognitive functions, as well as psychiatric symptoms. Firstly, we expected stronger moderation effects in men, with higher UA concentrations corresponding to better cognitive and psychiatric outcomes [38, 43]. Secondly, we expected lesser moderating effects in women, or even an inverse association between UA and cognitive functions as well as psychiatric symptoms, with female patients having better preserved outcomes in the presence of lowered levels of UA [37]. Finally, the effects of sex and UA when taking in consideration motor symptom asymmetry were explored.

Methods

Participants

The analyzed data were obtained from the Parkinson's Progression Marker Initiative (PPMI), an international and multicenter longitudinal study launched in 2010, aiming to identify progression biomarkers of PD [44]. The study officially enrolled 426 de novo, untreated PD patients [413 asymmetric motor symptom onset, 13 symmetric motor symptom onset (not included in this study) and 196 healthy controls (HC)]. Baseline, 1-year, 3-year and 5-year follow-up measurements were retained for the present paper. Inclusion criteria for participants was being aged above 30 years old; having newly diagnosed PD (2 years or less); being untreated with PD medication; having two of the following symptoms: resting tremor, bradykinesia and rigidity, or either asymmetric resting tremor, or asymmetric bradykinesia; having an imaging confirmation of a dopamine transporter deficit. Sex was defined as genetically confirmed sex, which was consistent with gender for all participants [45]. The asymmetry of motor symptoms was determined by a clinician at the time of diagnosis, based on the lateralized items of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale [46, 47].

A total of six groups were defined for this study: (1) PD patients with predominantly left-sided motor symptoms (LPD) at the onset of the disease, divided in male (LPDm; $n=105$) and female (LPDf; $n=74$) subgroups; (2) PD patients with predominantly right-sided motor symptoms (RPD) at the onset of the disease, divided in male (RPDm; $n=163$) and female (RPDf; $n=71$) subgroups;

and (3) HC, both male (HCm; $n=126$) and female (HCf; $n=70$), with no clinically significant neurological disorders (see Table 1). No significant differences were observed between the 6 subgroups for sociodemographic outcomes, except for race [with a majority of White individuals in all subgroups ($>90\%$); results seem to be driven by a lesser diversity in the RPDm group] and initial PD symptomatology (LPDf; LPDm; RPDf; RPDm) (see Table 1).

Ethics

The PPMI study is registered with ClinicalTrials.gov (NCT01141023). All participating sites received approval from an ethical standards committee on human experimentation prior to study initiation. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines following approval of the local ethics committees of the participating sites. Written informed consent for research was obtained from all individuals taking part in the study. The data used in the preparation of this article were obtained from the PPMI open access database. For more information regarding the study's protocol, research documentations and standard operating procedures, including ethical submissions and approvals, please visit <https://www.ppmi-info.org/study-design/research-documents-and-sops>.

www.ppmi-info.org/study-design/research-documents-and-sops.

Measured outcomes

Participants underwent comprehensive clinical, imaging and biosampling assessments. Regarding clinical aspects, the MDS-UPDRS [48] and Hoehn and Yahr scale [49] were used to evaluate motor aspects, and Epworth Sleepiness Scale (ESS) [50] was used to measure daytime sleepiness. Among cognitive assessments, the Montreal Cognitive Assessment (MoCA) [51], Hopkins Verbal Learning Test (HVLT) [52], Benton Judgment of Line Orientation Test (BJLOT) [53], semantic fluency [54] and Symbol Digit Modalities Test (SDMT) [55] were used. The Geriatric Depression Scale (GDS) [56] and State-Trait Anxiety Inventory (STAI) [57] were used to assess psychiatric symptoms. Blood sampling was used to measure plasma levels of UA at baseline and at each 12-month follow-up visit. Forty milliliters of venous whole blood was collected and sent to a central laboratory for analysis, thus guaranteeing identical analysis methods and consistent normal ranges.

Data analysis

In order to assess the relationships between UA, sex and motor symptom asymmetry on cognitive and psychiatric

Table 1 Sociodemographic and clinical variables at the baseline for each group (LPDf; LPDm; RPDf; RPDm; HCf; HCm)

	LPDf ($n=74$)	LPDm ($n=105$)	RPDf ($n=71$)	RPDm ($n=163$)	HCf ($n=70$)	HCm ($n=126$)	K-W/Chi ²
Age in years (mean \pm SD)	60.16 (± 10.71)	60.53 (± 9.55)	61.13 (± 8.35)	62.79 (± 9.75)	59.37 (± 11.70)	61.62 (± 10.92)	0.103
Education in years (mean \pm SD)	15.19 (± 3.20)	15.58 (± 2.80)	15.31 (± 3.02)	15.74 (± 3.00)	15.49 (± 2.72)	16.35 (± 2.95)	0.088
Race [White; Black; Asian; other] (in %)	91.89; 0; 2.70; 5.41	91.43; 2.86; 3.81; 1.90	90.14; 2.81; 1.41; 5.63	95.71; 0; 0; 4.29	91.43; 4.29; 1.43; 2.86	92.86; 5.56; 0; 1.59	0.031
Age of onset in years (mean \pm SD)	58.13 (± 10.94)	58.61 (± 9.90)	58.87 (± 8.73)	60.84 (± 9.93)	–	–	0.070
Age at diagnostic in years (mean \pm SD)	59.58 (± 10.68)	60.05 (± 9.60)	60.52 (± 8.36)	62.22 (± 9.68)	–	–	0.078
Initial symptom (at diagnosis)							
Resting tremor	No: 17.57%	No: 26.67%	No: 25.35%	No: 17.79%	No: 100.00%	No: 100.00%	0.230
	Yes: 82.43%	Yes: 73.33%	Yes: 74.65%	Yes: 82.21%	Yes: 0.00%	Yes: 0.00%	
Rigidity	No: 29.73%	No: 19.05%	No: 32.39%	No: 20.86%	No: 100.00%	No: 100.00%	0.095
	Yes: 70.27%	Yes: 80.95%	Yes: 67.61%	Yes: 79.14%	Yes: 0.00%	Yes: 0.00%	
Bradykinesia	No: 16.22%	No: 11.43%	No: 22.54%	No: 20.25%	No: 100.00%	No: 100.00%	0.186
	Yes: 83.78%	Yes: 88.57%	Yes: 77.46%	Yes: 79.75%	Yes: 0.00%	Yes: 0.00%	
Postural instability	No: 91.89%	No: 92.38%	No: 94.37%	No: 94.48%	No: 100.00%	No: 100.00%	0.833
	Yes: 8.11%	Yes: 7.62%	Yes: 5.63%	Yes: 5.52%	Yes: 0.00%	Yes: 0.00%	
Other	No: 79.73%	No: 87.62%	No: 81.69%	No: 84.66%	No: 100.00%	No: 100.00%	0.500
	Yes: 20.27%	Yes: 12.38%	Yes: 18.31%	Yes: 15.34%	Yes: 0.00%	Yes: 0.00%	

f female, HC healthy controls, LPD patients with Parkinson's disease (PD) who exhibit predominantly left-sided motor symptoms, m male, RPD patients with PD who exhibit predominantly right-sided motor symptoms, K-W Kruskal–Wallis test, M-W Mann–Whitney U test, SD standard deviation




Fig. 1 Conceptual model of a three-way interaction between motor symptom asymmetry, UA and sex. A conceptual representation of three-way interaction (moderated moderation) effects of UA and sex on the relationship between motor symptom asymmetry and cognitive–psychiatric symptoms, extracted from PROCESS macro for SPSS (Model 3)

outcomes, we tested a conceptual three-way interaction model, also known as moderated moderation model, using the Hayes PROCESS macro [42]. The three-way moderation model included motor symptom asymmetry (multicategorical indicator coding system for RPD and LPD) as the predictor variable, cognitive and psychiatric symptoms as outcome variables, UA as the primary moderator (M) and sex as the secondary moderator (W; Fig. 1). This model was tested for each outcome, namely cognitive (MoCA, HVLt immediate and delayed recall, BJLOT, SDMT and semantic fluency scores) and psychiatric (GDS and STAI scores) variables, at each timepoint. Given the impact of age, racial background, levodopa medication and education on individuals' UA serum concentrations and NMS [28, 58, 59], we adjusted for these three variables by including them as covariates in the models. The Davidson–Mackinnon estimator of heteroskedasticity-consistent standard error was used in order to reduce the possible effects of heteroskedasticity on the inference of regression estimates [60]. All data analyses were conducted in SPSS 26.

Results

Moderated moderation in the relationship between motor symptom asymmetry and cognitive and psychiatric symptoms

The three-way interaction models yielded interesting results regarding the moderating effects of UA and sex on the relationship between motor symptom asymmetry, clinically measured using the MDS-UPDRS III scores at disease onset, and cognitive and psychiatric symptoms. A total of four models showed a statistically significant interaction between motor symptom asymmetry, UA and sex at 1-year follow-up (see Table 2). Model 1 showed a statistically significant interaction between the LPD group, UA levels and sex on immediate memory scores. The overall model accounted for 24.46% of the

Table 2 Moderated moderation models showing three-way interactions between motor symptom asymmetry, UA and sex on cognitive and psychiatric outcomes at 1-year follow-up

	<i>B</i>	<i>SE</i>	95% <i>CI</i>	
Model 1: three-way interactions on HVLt immediate recall				
LPD×UA	0.060	0.031	−0.002	0.122
RPD×UA	−0.016	0.034	−0.083	0.051
LPD×sex	−2.40	1.99	−6.31	1.52
RPD×sex	0.25	2.34	−4.36	4.86
UA×sex	0.015	0.010	−0.004	0.034
LPD×UA×sex	−0.056	0.026	−0.107	−0.005*
RPD×UA×sex	0.005	0.029	−0.051	0.062
Model 2: three-way interactions on HVLt delayed recall				
LPD×UA	0.038	0.015	0.009	0.067*
RPD×UA	−0.008	0.018	−0.044	0.028
LPD×sex	−1.137	0.886	−2.88	0.605
RPD×sex	−0.244	1.11	−2.44	1.95
UA×sex	0.006	0.005	−0.003	0.016
LPD×UA×sex	−0.034	0.011	−0.0553	−0.012*
RPD×UA×sex	0.002	0.016	−0.030	0.033
Model 3: three-way interactions on SDMT				
LPD×UA	0.021	0.060	−0.097	0.138
RPD×UA	−0.106	0.060	−0.224	0.013
LPD×sex	−2.43	3.30	−8.93	4.06
RPD×sex	6.49	3.83	−1.05	14.03
UA×sex	0.000	0.027	−0.053	0.053
LPD×UA×sex	−0.019	0.043	−0.105	0.067
RPD×UA×sex	0.101	0.047	0.009	0.193*
Model 4: three-way interactions on ESS				
LPD×UA	0.003	0.026	−0.048	0.053
RPD×UA	0.035	0.022	−0.008	0.078
LPD×sex	0.054	1.78	−3.45	3.56
RPD×sex	−3.45	1.37	−6.15	−0.748*
UA×sex	0.001	0.008	−0.015	0.017
LPD×UA×sex	0.007	0.022	−0.036	0.050
RPD×UA×sex	−0.036	0.016	−0.067	−0.005*

Model includes the following demographic control variables: age, education, levodopa medication and racial background

B Unstandardized regression coefficient, *CI* Confidence Intervals, *ESS* Epworth Sleepiness Scale, *HVLt* Hopkins Verbal Learning Test, *LPD* patients with Parkinson's disease (PD) who exhibit predominantly left-sided motor symptoms, *RPD* patients with PD who exhibit predominantly right-sided motor symptoms, *SE* standard error of the regression, *SDMT* Symbol Digit Modalities test, *UA* uric acid

Statistically significant relationships where $p < 0.05$ are reported with an asterisk

total variance of immediate memory recall scores [$F(15, 372) = 8.44, p < 0.001$], with the interaction itself accounting for 1.63% of the total variance. Model 2 also displayed a significant interaction between the LPD group, UA levels and sex on delayed memory scores. The overall model accounted for 21.73% of the total variance [$F(15,$

372)=9.11, $p<0.001$], with the three-way interaction accounting in itself for 2.07% of the total variance. These two first models demonstrate that LPDf patients seem to be more affected by UA variability than their male counterparts, showing higher memory scores in the presence of lower levels of UA (see Fig. 2A, B). Model 3, on the other hand, demonstrated a statistically significant interaction between the RPD group, UA and sex for processing speed scores. The overall model accounted for 38.89% of the total variance of SDMT scores [$F(15, 372)=13.61$,

$p<0.001$], with the three-way interaction accounting in itself for 0.87% of the total variance. Interestingly, this model revealed better processing speed scores in the presence of higher UA concentrations in RPDf patients (see Fig. 2C). Finally, model 4 showed a statistically significant interaction between the RPD group, UA levels and sex on sleepiness. The overall model accounted for 9.09% of the total variance of ESS scores [$F(15, 372)=2.79$, $p<0.001$], with solely the three-way interaction accounting for 1.00% of the total variance. This model revealed




Fig. 2 Three-way interaction plot of motor symptom asymmetry, UA and sex on cognitive and psychiatric outcomes. Significant three-way interactions were noted for immediate memory (A), delayed memory (B), processing speed (C) and sleepiness (D). Analyses were performed using the PROCESS macro for SPSS (Model 3). Model includes the following covariables: age, education, levodopa medication and racial background. HC healthy controls, HVL Hopkins Verbal Learning Test, LPD patients with Parkinson's disease (PD) who exhibit predominantly left-sided motor symptoms, RPD patients with PD who exhibit predominantly right-sided motor symptoms, UA uric acid

that RPDf patients seem to show lower daytime sleepiness in the presence of higher UA levels (see Fig. 2D). No significant three-way interactions were found for years 3 and 5. Moreover, PD male patients did not seem to exhibit any effect of UA variability on cognitive and psychiatric measurements.

While supporting our hypothesis of significant moderating effects of sex and UA on the relationship between motor symptom asymmetry and neuropsychiatric outcomes, these results do not go in the direction of our first prediction of a stronger moderation effect in men. Indeed, no significant and positive associations between UA concentrations and neuropsychological performances were found in male RPD and LPD patients. The results do however comfort our second prediction of an inverse association between UA and cognitive performances in female patients, with better outcomes noted in the presence of lower UA levels for the LPDf group. The simultaneous interaction between motor symptom asymmetry, sex and UA was explored, showing an inverse moderating effect of UA depending on the side of motor symptomatology and the type of NMS in women, with RPDf patients showing less sleepiness and improved processing speed in the presence of higher UA concentrations.

Cognitive and psychiatric outcomes according to motor symptom asymmetry and sex

Secondary analyses were conducted to better characterize the profile of each subgroup. Inter-group and intra-group comparisons with respect to motor asymmetry and sex were carried out for cognitive scores (Additional file 1: Tables S1.1, S1.2 and S1.3, Fig. S1), psychiatric scores (Additional file 1: Tables S2.1, S2.2 and S2.3, Fig. S2), as well as motor severity symptoms alongside serum UA and Levodopa Daily medication (Additional file 1: Tables S3.1, S3.2 and S3.3, Fig. S3).

In brief, female patients had overall better cognitive performances compared to their male counterparts, for the MoCA ($p < 0.05$), HVLIT immediate and delayed recall ($p < 0.02$), BJLOT ($p < 0.008$), SDMT ($p < 0.03$) and semantic fluency ($p < 0.003$). More so, the RPDf subgroup demonstrated better cognitive functioning, notably for the MoCA ($p = 0.002$), HVLIT immediate and delayed recall ($p < 0.023$) and semantic fluency ($p < 0.03$), when compared to HC and their male counterparts. They also showed the least decline over time (noted only for the BJLOT at Year 1, $p < 0.007$). Similar patterns of results were observed for psychiatric measures, with the RPDf group demonstrating lesser symptoms and the least decline over time when compared to other groups. It is noteworthy that RPDf patients exhibited the lowest concentrations of UA at certain timepoints ($p < 0.04$). When compared to the rest of the subgroups, RPDm patients

were most affected on multiple domains, such as global efficiency ($p < 0.032$), short and long-term memory ($p < 0.03$) as well as processing speed ($p < 0.012$). The RPDm group also displayed the most important decline over time in terms of sleepiness ($p < 0.001$), depressive symptoms ($p < 0.004$) and sleep disturbances ($p < 0.001$). Finally, significant negative correlations were highlighted between the scores of the ESS and the SDMT for the whole sample and for each patient subgroup, except for LPDf patients (see Additional file 1: Table S4). Further information can be found in the Additional file 1.

Discussion

The present study aimed to better understand the relationships between UA, sex and motor symptom asymmetry at disease onset on cognitive functions and psychiatric symptoms in early-stage PD patients. To this end, we performed three-way interaction models using data from the Parkinson's Progression Marker Initiative. We expected sex and UA to significantly moderate the relationship between motor symptom asymmetry and cognitive–psychiatric symptoms, with stronger moderation effects in men, where higher UA concentrations would correspond to better cognitive and psychiatric outcomes. Conversely, we expected lesser moderating effects in women, or even an inverse association between UA and cognitive–psychiatric symptoms, with female patients having preserved outcomes in the presence of lowered UA levels. Finally, the effects of sex and UA when taking in consideration motor symptom asymmetry were explored. Results of our three-way interactions partially confirmed our predictions regarding certain cognitive functions and psychiatric symptoms at 1-year follow-up, offering strong support for a significant moderation of UA and sex on the relationship between motor symptom asymmetry and cognitive–psychiatric symptoms. Indeed, as expected, significant three-way interactions were found for the LPD and RPD female subgroups. For the LPDf subgroup, higher short- and long-term memory performances were associated to lower concentrations of UA, while for the RPDf subgroup, higher daytime sleepiness and slower processing speed were associated to lower concentrations of UA. Finally, the male subgroups did not seem to benefit from the modulating effects of UA.

Three patterns of results seem to stand out from the current findings. First, the results of our three-way interactions corroborate previous findings of a deleterious effect of elevated UA concentrations on certain cognitive functions, such as episodic memory, in women [37]. In this regard, lower serum UA could be an indicator of an endogenous capacity to cope with PD-related cerebral oxidative stress induced by multiple neuropathological

factors, such as protein misfolding, mitochondrial dysfunction, excitotoxicity, etc. [61]. Decreased UA serum concentrations in early PD patients would thus reflect an efficient mobilization of peripheral antioxidant resources to the brain. This phenomenon has also been observed in post-traumatic brain injury studies showing that decreased UA serum levels concurred with increased UA concentrations in damaged brain tissues [62].

Second, the association between UA, sex and cognitive and psychiatric outcomes seems to differ depending on the side of motor symptomatology and on the nature of the evaluated processes. For instance, in contrast to the associations found between lower UA levels and better cognitive performance in LPDf patients, RPDf patients with lower UA levels presented higher daytime sleepiness. Multiple studies have found lower serum UA levels to be associated with increased fatigue and sleepiness in PD [30, 31] (for review, see [63]), and in other clinical populations (e.g., stroke patients [64]). Moreover, previous findings have also linked lowered levels of UA with higher psychiatric manifestations in early PD [29]. Interestingly, secondary analyses highlighted significant negative correlations between higher daytime sleepiness and reduced processing speed in the RPDf group but not in the LPDf group, indicating that increased fatigue might explain the lower performances on the SDMT in the presence of decreased serum UA levels solely for the former group. Thus, while lower serum UA seems to be beneficial for preserving higher cognitive functions (such as memory) in female patients with predominantly left-sided symptoms, it might predispose to higher sleepiness, and thus reduced processing speed, in female patients with predominantly right-sided symptoms.

Third, and finally, certain cognitive functions and psychiatric assessments were not significantly associated with UA, sex nor motor symptom asymmetry. This could be explained by the fact that a substantial part of cognitive and affective processes is underpinned by bilateral neuronal networks, implicating thus a potential influence of compensatory processes at the beginning of the pathology [65]. Moreover, complex interactions with other biomarkers (e.g., total-tau; α -synuclein; A β 42), for which distinct profiles have been recently highlighted between LPD and RPD patients [66, 67] might explain these results. Therefore, there seem to be distinct mechanisms through which UA moderates cognitive and psychiatric symptoms in early PD, notably depending on sex and motor symptom asymmetry.

Secondary analyses (detailed in Additional file 1) allowed us to further understand the clinical profiles of the subgroups. In essence, the RPDf group showed the least cognitive and psychiatric symptoms, while LPDf patients seemed more impaired in terms of cognitive

functions and displayed higher psychiatric symptoms over time. Both male patient groups had overall lower cognitive performances, not to mention more significant peioration in time, especially for the RPDm subgroup. These results comfort previous studies that found greater cognitive impairment in PD men than women [68], as well as recent longitudinal studies in early and advanced asymmetric PD that found a greater progression of cognitive impairment in RPD, specifically for global cognitive efficiency and memory function, alongside higher levels of apathy, suggesting a potential risk factor for dementia associated with PD. Conversely, results for LPD patients have revealed higher psychiatric symptoms, such as depression and anxiety, as well as emotional recognition disorders [10, 66, 69–71]. One explanation could reside in sex-related differences in hemispheric lateralization that might further allow to understand the observed cognitive and psychiatric discrepancies between subgroups. Indeed, studies tend to show greater hemispheric lateralization in men than women, with men demonstrating greater rightward connectivity, and women showing greater leftward connectivity [57]. Greater rightward lateralization in men could translate in weaker leftward plasticity, leaving the RPDm subgroup more vulnerable to the effects of pathological aging [58]. This is of particular importance as the left hemisphere has been shown to present an important vulnerability in neurodegenerative diseases, such as PD [17, 59]. On the contrary, lesser hemispheric lateralization in female PD patients, alongside a higher leftward cognitive reserve, would enable RPDf patients to better compensate for the effects of their prevalent left-hemispheric neurodegeneration.

Several limitations are noted for the present study. First, while we aimed to control for pertinent confounding variables in order to improve robustness, multiple other factors can influence purine metabolism and UA synthesis, notably diet and sex hormones [72]. It would be pertinent for future studies to better understand the interactions between sex-specific hormones, UA and alimentation in PD. Second, the models were established by yearly follow-up, transversally limiting data interpretation. It would be interesting for future studies to investigate the effects of sex and UA on the evolution of NMS using longitudinal approaches, such as generalized estimating equation modeling. Third, limitations regarding cognitive and psychiatric symptom testing should be mentioned. Notably, not all neuropsychological functions were assessed, such as inhibitory control or language. Also, assessments of psychiatric symptoms were done using only questionnaires. Fourthly, quality of life, an outcome that might also be influenced by sex and motor symptom asymmetry [69], was not assessed. Finally, as the association between serum UA and neurologic

dysfunction appears to be non-linear (possibly U-shaped [34]), the changes in the dynamic relationship between UA and NMS throughout the course of the disease merit further investigation.

Perspectives and significance

In summary, three-way interaction modeling was used in the present work, highlighting significant moderation of serum UA and sex on cognitive and psychiatric symptoms, depending on motor symptom asymmetry. Indeed, while lower serum UA appears to be associated with better memory performances in LPDf patients, it might predispose to higher sleepiness and reduced psychomotor speed in RPDf patients. Male patients, however, did not seem to benefit from the modulating effects of UA. Furthermore, RPDf patients displayed overall the most preserved cognitive and psychiatric outcomes, while RPDm patients were particularly impaired in these realms. Thus, the evolution of the disease in its early stages seems to differ between male and female patients according to motor symptom asymmetry, owing to physiological and cerebral differences between the two sexes. These findings point out to a growing body of literature addressing sex-based differences in the pathophysiology, treatment and clinical outcomes of patients with PD. Future studies will allow to better untangle the interactions occurring between biological processes in asymmetric Parkinson's disease, and how they differentially impact male and female patients during the disease's course.

Conclusion

The present study helps provide a better understanding of the interactions occurring between UA, sex, and motor symptom asymmetry in the manifestation of cognitive and psychiatric symptoms in early PD. To our knowledge, it is the first study providing compelling evidence of different profiles in early PD based on motor symptom asymmetry at disease onset and sex, while accounting for the moderating role of serum UA. This may hold important clinical implications for NMS management in early-stage PD patients, with RPDm patients presenting greater vulnerability compared to their female counterparts.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13293-023-00510-1>.

Additional file 1: Table S1.1. Cognitive scores for each PD subgroup and HC at each timepoint. **Table S1.2.** Intergroup comparisons at each timepoint of cognitive scores for each PD subgroup and HC. **Table S1.3.** Intragroup comparisons of cognitive scores for each PD subgroup and HC. **Figure S1.** Evolution of cognitive scores for each PD subgroup and HC. **Table S2.1.** Psychiatric scores for each PD subgroup and HC at each

timepoint. **Table S2.2.** Intergroup comparisons at each timepoint of psychiatric scores for each PD subgroup and HC. **Table S2.3.** Intragroup comparisons of psychiatric scores for each PD subgroup and HC. **Figure S2.** Evolution of psychiatric scores for each PD subgroup and HC. **Table S3.1.** Motor and serum uric acid scores for each PD subgroup and HC at each timepoint. **Table S3.2.** Intergroup comparisons at each timepoint of motor and serum uric acid outcomes for each PD subgroup and HC. **Table S3.3.** Intragroup comparisons of motor scores and serum uric acid for each PD subgroup and HC. **Figure S3.** Evolution of motor and serum uric acid outcomes for each PD subgroup and HC. **Table S4.** Correlation between the Epworth sleepiness scale scores and the Symbol Digit Modalities Test scores for the whole sample and each subgroup.

Acknowledgements

This work was made possible through the Parkinson's Progression Marker Initiative—a public–private partnership funded by the Michael J. Fox Foundation for Parkinson's Research funding partners 4D Pharma, Abbvie, Acurex Therapeutics, Allergan, Amatus Therapeutics, ASAP, Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol-Myers Squibb, Calico, Celgene, Dacapo Brain Science, Denali, The Edmond J. Safra Foundation, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine Biosciences, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics.

Author contributions

All authors contributed to the study conception and design. Analysis was performed by IMC, PV and JAP. The first draft of the manuscript was written by IMC and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by University of Geneva. This work was supported by the Swiss National Foundation, grant no. 105314_182221 (PI: Dr. Julie Anne Péron). The funders had no role in data collection, discussion of content, preparation of the manuscript, or decision to publish.

Availability of data and materials

All data were extracted from the PPMI funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners. Further details regarding data collection and measured outcomes have been previously published [44] and are available at <http://www.ppmi-info.org/>.

Declarations

Ethics approval and consent to participate

Participating PPMI sites received prior approval from appropriate ethical standards committees on human experimentation before study initiation. Written informed consent for research was obtained from all individuals taking part in the study. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines following approval of the local ethics committees of the participating sites.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Clinical and Experimental Neuropsychology Laboratory, Faculty of Psychology and Educational Sciences, University of Geneva, 40 Bd du Pont d'Arve, 1205 Geneva, Switzerland. ²Neurology Department, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland.

Received: 30 January 2023 Accepted: 17 April 2023

Published online: 04 May 2023

References

- Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. *Eur J Neurol*. 2013;20:16–34.
- Agosta S, Magnago D, Galante E, Ferraro F, Magherini A, di Giacompo R, Miceli G, Battelli L. Lateralized cognitive functions in Parkinson's patients: a behavioral approach for the early detection of sustained attention deficits. *Brain Res*. 2020;1726: 146486.
- Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson's disease. *Lancet Neurol*. 2018;17:559–68.
- Riederer P, Jellinger KA, Kolber P, Hipp G, Sian-Hülsmann J, Krüger R. Lateralisation in Parkinson disease. *Cell Tissue Res*. 2018;373:297–312.
- Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. *Nat Rev Neurosci*. 2017;18:435–50.
- Cubo E, Martín PM, Martín-González JA, et al. Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. *Mov Disord*. 2010;25:70–5.
- Amick MM, Grace J, Chou KL. Body side of motor symptom onset in Parkinson's disease is associated with memory performance. *J Int Neuro-psychol Soc*. 2006;12:736–40.
- Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Crimes JD, Chase TN. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. *Can J Neurol Sci*. 1992;19:163–9.
- Cooper CA, Mikos AE, Wood MF, Kirsch-Darrow L, Jacobson CE, Okun MS, Rodriguez RL, Bowers D, Fernandez HH. Does laterality of motor impairment tell us something about cognition in Parkinson disease? *Parkinsonism Relat Disord*. 2009;15:315–7.
- Voruz P, Le Jeune F, Haegelen C, et al. Motor symptom asymmetry in Parkinson's disease predicts emotional outcome following subthalamic nucleus deep brain stimulation. *Neuropsychologia*. 2020;144: 107494.
- Huber SJ, Miller H, Bohaska L, Christy JA, Bornstein RA. Asymmetrical cognitive differences associated with hemiparkinsonism. *Arch Clin Neuropsychol*. 1992;7:471–80.
- Karádi K, Lucza T, Aschermann Z, Komoly S, Deli G, Bosnyák E, Ács P, Horváth R, Janszky J, Kovács N. Visuospatial impairment in Parkinson's disease: the role of laterality. *Asymmetries Body Brain Cogn*. 2014;20:112–27. <https://doi.org/10.1080/1357650X.2014.936444>.
- Poletti M, Frosini D, Pagni C, et al. The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. *J Clin Exp Neuropsychol*. 2013;35:124–31. <https://doi.org/10.1080/13803395.2012.751966>.
- Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex: one decade on. *Trends Cogn Sci*. 2014;18:177–85.
- Mirabella G, Fragola M, Giannini G, Modugno N, Lakens D. Inhibitory control is not lateralized in Parkinson's patients. *Neuropsychologia*. 2017;102:177–89.
- Di Caprio V, Modugno N, Mancini C, Olivola E, Mirabella G. Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition. *Mov Disord*. 2020;35:409–18.
- Mirabella G, Iaconelli S, Romanelli P, Modugno N, Lena F, Manfredi M, Cantore G. Deep brain stimulation of subthalamic nuclei affects arm response inhibition in Parkinson's patients. *Cereb Cortex*. 2012;22:1124–32.
- Mirabella G, Iaconelli S, Modugno N, Giannini G, Lena F, Cantore G. Stimulation of subthalamic nuclei restores a near normal planning strategy in Parkinson's patients. *PLoS ONE*. 2013;8: e62793.
- Mancini C, Modugno N, Santilli M, Pavone L, Grillea G, Morace R, Mirabella G. Unilateral stimulation of subthalamic nucleus does not affect inhibitory control. *Front Neurol*. 2019;9:1149.
- Pellicano C, Assogna F, Cravello L, Langella R, Caltagirone C, Spalletta G, Pontieri FE. Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients. *Parkinsonism Relat Disord*. 2015;21:1096–100.
- Modestino EJ, Amenechi C, Reinhofer AM, O'Toole P. Side-of-onset of Parkinson's disease in relation to neuropsychological measures. *Brain Behav*. 2017;7:e00590–e00590.
- Ham JH, Lee JJ, Kim JS, Lee PH, Sohn YH. Is dominant-side onset associated with a better motor compensation in Parkinson's disease? *Mov Disord*. 2015;30:1921–5.
- Claassen DO, McDonnell KE, Donahue M, et al. Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. *Brain Behav*. 2016;6: e00573.
- Rotenberg VS. The peculiarity of the right-hemisphere function in depression: solving the paradoxes. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004;28:1–13.
- Kurlawala Z, Shadowen PH, McMillan JD, Beverly LJ, Friedland RP. Progression of nonmotor symptoms in Parkinson's disease by sex and motor laterality. *Parkinsons Dis*. 2021. <https://doi.org/10.1155/2021/8898887>.
- Yu Z, Zhang S, Wang D, Fan M, Gao F, Sun W, Li Z, Li S. The significance of uric acid in the diagnosis and treatment of Parkinson disease. *Medicine*. 2017. <https://doi.org/10.1097/MD.00000000000008502>.
- Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, Vassilopoulos D. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. *Clin Neurol Neurosurg*. 2009;111:724–8.
- Zhou Z, Zhong S, Liang Y, Zhang X, Zhang R, Kang K, Qu H, Xu Y, Zhao C, Zhao M. Serum uric acid and the risk of dementia: a systematic review and meta-analysis. *Front Aging Neurosci*. 2021. <https://doi.org/10.3389/FNAGI.2021.625690>.
- Moccia M, Picillo M, Erro R, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease. *Eur J Neurol*. 2015;22:93–8.
- van Wamelen DJ, Taddei RN, Calvano A, Titova N, Leta V, Shtuchniy I, Jenner P, Martinez-Martin P, Katunina E, Chaudhuri KR. Serum uric acid levels and non-motor symptoms in Parkinson's disease. *J Parkinsons Dis*. 2020;10:1003–10.
- Huang X, Ng SYE, Chia NSY, et al. Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson's disease: PALS study. *Parkinsonism Relat Disord*. 2018;55:50–4.
- Fukae J, Ishikawa KI, Hatano T, Yoritaka A, Takanashi M, Shimo Y, Tsugawa J, Tsuboi Y, Hattori N. Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson's disease patients. *J Parkinsons Dis*. 2014;4:499–505.
- Lolkha P, Wongwan P, Kulkantrakorn K. Association between serum uric acid and motor subtypes of Parkinson's disease. *J Clin Neurosci*. 2015;22:1264–7.
- Latourte A, Bardin T, Richette P. Uric acid and cognitive decline: a double-edged sword? *Curr Opin Rheumatol*. 2018;30:183–7.
- Cicero AFG, Desideri G, Grossi G, Urso R, Rosticci M, D'Addato S, Borghi C. Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: data from the Brisighella study. *Intern Emerg Med*. 2015;10:25–31.
- Verhaaren BFJ, Vernooij MW, Deeghan A, et al. The relation of uric acid to brain atrophy and cognition: the Rotterdam scan study. *Neuroepidemiology*. 2013;41:29–34.
- Vannorsdall TD, Kueider AM, Carlson MC, Schretlen DJ. Higher baseline serum uric acid is associated with poorer cognition but not rates of cognitive decline in women. *Exp Gerontol*. 2014;60:136–9.
- Li J, Dong BR, Lin P, Zhang J, Liu GJ. Association of cognitive function with serum uric acid level among Chinese nonagenarians and centenarians. *Exp Gerontol*. 2010;45:331–5.
- Jain S, Ton TG, Boudreau RM, Yang M, Thacker EL, Studenski S, Longstreth WT, Strotmeyer ES, Newman AB. The risk of Parkinson disease associated with urate in a community-based cohort of older adults. *Neuroepidemiology*. 2011;36:223–9.
- Davidson S, Wagenaar R, Young D, Cronin-Golomb A. Impact of optic flow perception and egocentric coordinates on veering in Parkinson's disease. *Brain*. 2008;131:2882–93.
- Bentivoglio AR, Lo Monaco MR, Liperoti R, Fusco D, Di Stasio E, Tondinelli A, Marzullo D, Maino A, Cipriani MC, Silveri MC. Gender may be related to the side of the motor syndrome and cognition in idiopathic Parkinson's disease. *Neurologia*. 2021. <https://doi.org/10.1016/J.NRL.2021.01.009>.
- Hayes AF, Montoya AK, Rockwood NJ. The analysis of mechanisms and their contingencies: PROCESS versus structural equation modeling. *Australas Mark J*. 2017;25:76–81.
- Shen C, Guo Y, Luo W, Lin C, Ding M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. *Can J Neurol Sci*. 2013;40:73–9.
- Marek K, Jennings D, Lasch S, et al. The Parkinson progression marker initiative (PPMI). *Prog Neurobiol*. 2011;95:629–35.
- Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. *Lancet Neurol*. 2017;16:908–16.

46. Benis D, Haegelen C, Voruz P, Pierce J, Milesi V, Houvenaghel JF, Vérin M, Sauleau P, Grandjean D, Péron J. Subthalamic nucleus oscillations during vocal emotion processing are dependent of the motor asymmetry of Parkinson's disease. *Neuroimage*. 2020;222: 117215.
47. Thomasson M, Benis D, Voruz P, Saj A, Vérin M, Assal F, Grandjean D, Péron J. Crossed functional specialization between the basal ganglia and cerebellum during vocal emotion decoding: insights from stroke and Parkinson's disease. *Cogn Affect Behav Neurosci*. 2022;1:1–14.
48. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. *Mov Disord*. 2007;22:41–7.
49. Hoehn MM, Yahr MD. Parkinsonism. *Neurology*. 1967;17:427–427.
50. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;14:540–5.
51. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. the montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53:695–9.
52. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test—revised: normative data and analysis of inter-form and test–retest reliability. *Clinical Neuropsychol*. 1998;12:43–55.
53. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment: a clinical test. *Arch Neurol*. 1978;35:364–7.
54. Spreen O, Benton AL. Neurosensory center comprehensive examination for aphasia: manual of instructions (NCCEA). Victoria: University of Victoria; 1977.
55. Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Services; 1973.
56. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res*. 1982;17:37–49.
57. Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA. State-trait anxiety inventory. Palo Alto: Consulting Psychologists Press; 1983.
58. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model. *Mov Disord*. 2013;28:663–7.
59. Vieru E, Köksal A, Mutluay B, Dirican AC, Altunkaynak Y, Baybas S. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease. *Neurol Sci*. 2016;37:743–7.
60. Hayes AF, Cai L. Using heteroskedasticity-consistent standard error estimators in OLS regression: an introduction and software implementation. *Behav Res Methods*. 2007;39:709–22.
61. Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. *Exp Neurol*. 2017;298:210–24.
62. Liu H, He J, Zhong J, et al. Clinical and basic evaluation of the prognostic value of uric acid in traumatic brain injury. *Int J Med Sci*. 2018;15:1072–82.
63. Grażyńska A, Adamczewska K, Antoniuk S, Bień M, Toś M, Kufel J, Urbaś W, Siuda J. The influence of serum uric acid level on non-motor symptoms occurrence and severity in patients with idiopathic Parkinson's disease and atypical Parkinsonisms—a systematic review. *Medicina*. 2021;57:972.
64. Wu D, Wang L, Teng W, Huang K, Shang X. Correlation of fatigue during the acute stage of stroke with serum uric acid and glucose levels, depression, and disability. *Eur Neurol*. 2014;72:223–7.
65. Blesa J, Juri C, García-Cabezas MÁ, Adán R, Sánchez-González MÁ, Cavada C, Obeso JA. Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. *Front Syst Neurosci*. 2011;5:92.
66. Voruz P, Constantin IM, Péron JA. Biomarkers and non-motor symptoms as a function of motor symptom asymmetry in early Parkinson's disease. *Neuropsychologia*. 2022;177: 108419.
67. Fiorenzato E, Antonini A, Bisiacchi P, Weis L, Biundo R. Asymmetric dopamine transporter loss affects cognitive and motor progression in Parkinson's disease. *Mov Disord*. 2021;36:2303–13.
68. Nicoletti A, Vasta R, Mostile G, et al. Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk? *Parkinsonism Relat Disord*. 2017;35:69–74.
69. Voruz P, Pierce J, Ahrweiler K, Haegelen C, Sauleau P, Drapier S, Drapier D, Vérin M, Péron J. Motor symptom asymmetry predicts non-motor outcome and quality of life following STN DBS in Parkinson's disease. *Sci Rep*. 2022;12:1–9.
70. Voruz P, Haegelen C, Assal F, Drapier S, Drapier D, Sauleau P, Vérin M, Péron JA. Motor symptom asymmetry predicts cognitive and neuropsychiatric profile following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: a 5-year longitudinal study. *Arch Clin Neuropsychol*. 2023. <https://doi.org/10.1093/ARCLIN/ACAD013>.
71. Harris E, McNamara P, Durso R. Apathy in patients with parkinson disease as a function of side of onset. *J Geriatr Psychiatry Neurol*. 2013;26:95–104.
72. Hantikainen E, Trolle Lagerros Y, Ye W, Serafini M, Adami HO, Bellocchio R, Bonn S. Dietary antioxidants and the risk of Parkinson disease. *Neurology*. 2021;96:e895–903.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

